Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9833964 | 0.91 | MAPK14 (0.50) | MAPK14FPR2SCN9ACA2 | |
| SCHEMBL9833970 | 0.91 | MAPK14 (0.50) | MAPK14FPR2SCN9ACA2 | |
| SCHEMBL10387224 | 0.91 | MAPK14 (0.50) | MAPK14FPR2SCN9ACA2 | |
| SCHEMBL7595684 | 0.89 | MAPK14 (0.48) | MAPK14FFAR4 | |
| SCHEMBL9774729 | 0.86 | MAPK14 (0.53) | MAPK14CA2 | |
| SCHEMBL9774733 | 0.86 | MAPK14 (0.53) | MAPK14CA2 | |
| SCHEMBL8994562 | 0.84 | TDP1 (0.53) | MAPK14CA2 | |
| SCHEMBL19560079 | 0.82 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL4306726 | 0.82 | MAPK14 (0.45) | MAPK14JAK2NTRK1CCNKCDK12 | |
| SCHEMBL2878758 | 0.81 | MAPK14 (0.44) | MAPK14JAK2NTRK1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040027-A1 | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | KARRER FRIEDRICH (CH) | 2002-04-04 | — | — | US | disclosed |
| EP-0933998-A1 | METHOD FOR THE PREVENTION OF THE REINFESTATION OF WARM-BLOODED ANIMALS BY ECTOPARASITES | Novartis AG (CH) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998016107-A1 | METHOD FOR THE PREVENTION OF THE REINFESTATION OF WARM-BLOODED ANIMALS BY ECTOPARASITES | NOVARTIS AG (CH) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040027-A1 | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | SERPINC1, RXFP3, SERPINA3 | MAPK14 3197/4885JAK2 354/4885NTRK1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.